TrialBMJ open2017

Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.

Hiromichi Matsuoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.